← Back to All US Stocks

MDCE Stock Analysis 2026 - Medical Care Technologies Inc. AI Rating

MDCE OTC Services-Business Services, NEC NV CIK: 0001404593
Recently Updated • Analysis: Apr 1, 2026 • SEC Data: 2012-09-30
STRONG SELL
95% Conf
Pending
Analysis scheduled

📊 MDCE Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: $-901.8K
Current Ratio: 0.16x
Debt/Equity: N/A
EPS: $0.00
AI Rating: STRONG SELL with 95% confidence

Is MDCE a Good Investment? Thesis Analysis

Claude

Medical Care Technologies Inc. exhibits severe financial distress with negative stockholders' equity of -$228.5K, indicating the company is technically insolvent. The company is hemorrhaging cash with negative operating cash flow of -$895.6K and negative free cash flow of -$901.8K, while maintaining minimal liquidity (current ratio of 0.16x) and essentially no cash reserves ($742). With no revenue data available, persistent operating losses of -$6.7M, and zero insider buying activity, the company appears to be in terminal decline.

Why Buy MDCE? Key Strengths

Claude
  • + Minimal capital expenditure requirements ($6.2K) suggest low operational overhead
  • + Business Services sector provides potential for lean operations
  • + Small asset base ($1.2M) limits downside impact from liquidation

MDCE Investment Risks to Consider

Claude
  • ! Negative stockholders' equity represents insolvency and extinction risk
  • ! Severe liquidity crisis with current ratio of 0.16x - unable to meet short-term obligations
  • ! Negative operating cash flow of -$895.6K indicates unsustainable burn rate
  • ! No revenue visibility - fundamental business model viability unknown
  • ! Total liabilities exceed total assets by $200K despite minimal balance sheet
  • ! Data freshness from 2012 suggests potential delisting or dormant status
  • ! ROA of -586.3% demonstrates catastrophic asset productivity

Key Metrics to Watch

Claude
  • * Cash depletion timeline at current burn rate
  • * Any revenue generation or return to positive operating cash flow
  • * Stockholders' equity recovery or bankruptcy filing
  • * Updated SEC filings to confirm company status

MDCE Financial Metrics

Revenue
N/A
Net Income
$-6.8M
EPS (Diluted)
$0.00
Free Cash Flow
$-901.8K
Total Assets
$1.2M
Cash Position
$742.0

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

MDCE Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -586.3%
FCF Margin N/A

MDCE vs Default Sector

How Medical Care Technologies Inc. compares to Default sector averages

Net Margin
MDCE 0.0%
vs
Sector Avg 12.0%
MDCE Sector
ROE
MDCE 0.0%
vs
Sector Avg 15.0%
MDCE Sector
Current Ratio
MDCE 0.2x
vs
Sector Avg 1.8x
MDCE Sector
Debt/Equity
MDCE 0.0x
vs
Sector Avg 0.7x
MDCE Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is MDCE Overvalued or Undervalued?

Based on fundamental analysis, Medical Care Technologies Inc. has mixed fundamental signals relative to the Default sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

MDCE Balance Sheet & Liquidity

Current Ratio
0.16x
Quick Ratio
0.16x
Debt/Equity
N/A
Debt/Assets
119.8%
Interest Coverage
-7.83x
Long-term Debt
N/A

MDCE 5-Year Financial Trend & Growth Analysis

MDCE 5-year financial data:
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Medical Care Technologies Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.

MDCE Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

MDCE Capital Allocation

Operating Cash Flow
-$895.6K
Cash generated from operations
Capital Expenditures
$6.2K
Investment in assets
Dividends
None
No dividend program

MDCE SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for Medical Care Technologies Inc. (CIK: 0001404593)

📋 Recent SEC Filings

Date Form Document Action
Dec 3, 2012 4 xslF345X03/f4113012ags_medicalcare.xml View →
Nov 20, 2012 8-K f8k112012_medicalcare.htm View →
Nov 19, 2012 10-Q f10q0912_medicalcare.htm View →
Oct 17, 2012 SC 13D sc13d0512ags_medicalcare.htm View →
Oct 12, 2012 SC 13G sc13ga0412ags_medical.htm View →

Frequently Asked Questions about MDCE

What is the AI rating for MDCE?

Medical Care Technologies Inc. (MDCE) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are MDCE's key strengths?

Claude: Minimal capital expenditure requirements ($6.2K) suggest low operational overhead. Business Services sector provides potential for lean operations.

What are the risks of investing in MDCE?

Claude: Negative stockholders' equity represents insolvency and extinction risk. Severe liquidity crisis with current ratio of 0.16x - unable to meet short-term obligations.

What is MDCE's revenue and growth?

Medical Care Technologies Inc. reported revenue of N/A.

Does MDCE pay dividends?

Medical Care Technologies Inc. does not currently pay dividends.

Where can I find MDCE SEC filings?

Official SEC filings for Medical Care Technologies Inc. (CIK: 0001404593) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is MDCE's EPS?

Medical Care Technologies Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is MDCE a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Medical Care Technologies Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is MDCE stock overvalued or undervalued?

Valuation metrics for MDCE: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy MDCE stock in 2026?

Our dual AI analysis gives Medical Care Technologies Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is MDCE's free cash flow?

Medical Care Technologies Inc.'s operating cash flow is $-895.6K, with capital expenditures of $6.2K.

How does MDCE compare to other Default stocks?

Vs Default sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.16 (avg: 1.8).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 1, 2026 | Data as of: 2012-09-30 | Powered by Claude AI